Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Open Medicine

formerly Central European Journal of Medicine

Editor-in-Chief: Darzynkiewicz, Zbigniew

1 Issue per year


IMPACT FACTOR 2016 (Open Medicine): 0.294
IMPACT FACTOR 2016 (Central European Journal of Medicine): 0.116

CiteScore 2016: 0.28

SCImago Journal Rank (SJR) 2015: 0.140
Source Normalized Impact per Paper (SNIP) 2015: 0.154

Open Access
Online
ISSN
2391-5463
See all formats and pricing
More options …
Volume 9, Issue 1 (Feb 2014)

Issues

Beneficial neurohumoral profile in left ventricular systolic dysfunction following acute myocardial infarction

Giedrė Balčiūnaitė / Alfredas Rudys
  • Centre of Cardiology and Angiology, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania
  • Clinic of Cardiovascular disease, Vilnius University Medical Faculty, Vilnius, Lithuania
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Nelli Bičkauskaitė / Diana Zakarkaitė / Viktor Skorniakov / Jelena Čelutkienė / Aleksandras Laucevičius
  • Centre of Cardiology and Angiology, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania
  • Clinic of Cardiovascular disease, Vilnius University Medical Faculty, Vilnius, Lithuania
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2014-02-04 | DOI: https://doi.org/10.2478/s11536-012-0141-6
  • [1] Omland T., Aakvaag A., Bonarjee V.S., et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963–1969 http://dx.doi.org/10.1161/01.CIR.93.11.1963CrossrefGoogle Scholar

  • [2] Struthers A.D. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996;2:47–54 http://dx.doi.org/10.1016/S1071-9164(96)80009-1CrossrefGoogle Scholar

  • [3] Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341(10):709–717 http://dx.doi.org/10.1056/NEJM199909023411001CrossrefGoogle Scholar

  • [4] Rousseau M.F., Gurne O., Duprez D., Mieghem W., Robert A., Ahn S., Galanti.L, Ketelslegers J.M. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure. J Am Coll Cardiol 2002; Vol 40 Google Scholar

  • [5] Delyani, J.A., 2000. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int. 57, 1408–1411 http://dx.doi.org/10.1046/j.1523-1755.2000.00983.xCrossrefGoogle Scholar

  • [6] Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–1321. [Ephesus] http://dx.doi.org/10.1056/NEJMoa030207CrossrefGoogle Scholar

  • [7] Zannad F., McMurray J.J.V., Drexler H., Krum H., Van Veldhusein J.D., Swedberg K., Shi H., Vincent J., Pitt B. Rationale and design of the Eplerenone in mild patients hospitalization and survival study in heart failure (Emphasis-HF). Eur J Heart Fail 2010; 12(6): 617–622 http://dx.doi.org/10.1093/eurjhf/hfq049CrossrefGoogle Scholar

  • [8] ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. McMurray JJ., Adamopoulos S., Anker SD, Auricchio A., Böhm M., Dickstein K., Falk V., Filippatos G., Fonseca C., ESC Committee for Practice Guidelines. Eur J Heart Fail. 2012 Aug;14(8):803–869 http://dx.doi.org/10.1093/eurjhf/hfs105CrossrefGoogle Scholar

  • [9] Forman D.E., Butler J., Wang Y., Abraham W.T., O’Connor C.M. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004; 43: 61–67 http://dx.doi.org/10.1016/j.jacc.2003.07.031CrossrefGoogle Scholar

  • [10] Jose P., Skali H., Anavekar N., Tomson C., Krumholz H.M., Rouleau J.L., Moye L., Pfeffer M.A., Solomon S.D. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol. 2006;17:2886–2891 http://dx.doi.org/10.1681/ASN.2006010063CrossrefGoogle Scholar

  • [11] Anavekar N.S., McMurray J.J., Velazquez E.J., Solomon S.D., Kober L., Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285–1295 http://dx.doi.org/10.1056/NEJMoa041365CrossrefGoogle Scholar

  • [12] Anand I.S., Bishu K., Rector T.S., Ishani A., Kuskowski M.A., Cohn J.N. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensinconverting enzyme inhibitor in patients with moderate to severe heart failure. Circulation. 2009; 120:1577–1584 http://dx.doi.org/10.1161/CIRCULATIONAHA.109.853648CrossrefGoogle Scholar

  • [13] Francis G.S., Tang W.H. Pathophysiology of congestive heart failure. Rev Cardiovasc Med. 2003;4(Suppl 2):S14–S20 Google Scholar

  • [14] Weber K.T. Aldosterone in congestive heart failure. N Engl J Med. 2001;345(23):1689–1697 http://dx.doi.org/10.1056/NEJMra000050CrossrefGoogle Scholar

  • [15] Gradman A.H. Evolving understanding of the renin-angiotensin-aldosterone system: pathophysiology and targets for therapeutic intervention. Am Heart J 2009;157:S1–6 http://dx.doi.org/10.1016/j.ahj.2009.04.005Web of ScienceCrossrefGoogle Scholar

  • [16] Rouleau J.L., Packer M., Moye L., et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994;24:583–591 http://dx.doi.org/10.1016/0735-1097(94)90001-9CrossrefGoogle Scholar

  • [17] Hall C., Rouleau J.L., Moye L., et al. N-terminal proatrial natriuretic factor: an independent predictor of long-term prognosis after myocardial infarction. Circulation 1994;89:1934–42 http://dx.doi.org/10.1161/01.CIR.89.5.1934CrossrefGoogle Scholar

  • [18] Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N Engl J Med 1998;339:321–328 http://dx.doi.org/10.1056/NEJM199807303390507CrossrefGoogle Scholar

  • [19] Tsutamato T., Wada A., Maeda K., et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001;37:1228–1233 http://dx.doi.org/10.1016/S0735-1097(01)01116-0CrossrefGoogle Scholar

  • [20] Struthers A.D., MacDonald T.M. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004; 61:663–670 http://dx.doi.org/10.1016/j.cardiores.2003.11.037CrossrefGoogle Scholar

  • [21] Edelmann.F, Schmidt A.G., Gelbrich G., et al. Rationale and design of the “aldosterone receptor blockade in diastolic heart failure” trial: a doubleblind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). Eur J Heart Fail 2010; 12:874–882. http://dx.doi.org/10.1093/eurjhf/hfq087CrossrefWeb of ScienceGoogle Scholar

  • [22] Weber K.T., Brilla C.G.. Pathological hypertrophy and cardiac interstitium: fibrosis and reninangiotensin-aldosterone system. Circulation 1991;83:1849–1865 http://dx.doi.org/10.1161/01.CIR.83.6.1849CrossrefGoogle Scholar

  • [23] Silvestre J.S., Heymes C., Oubenaissa A., Robert V., Aupetit-Faisant B., Carayon A., Swynghedauw B., Delcayre C. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99: 2694–2701 http://dx.doi.org/10.1161/01.CIR.99.20.2694CrossrefGoogle Scholar

  • [24] MacFadyen R.J., Lee A.F., Morton J.J., Pringle S.D., Struthers A.D. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999; 82:57–61 CrossrefGoogle Scholar

  • [25] Struthers A.D. The clinical implications of aldosterone escape in congestive heart failure. Eur J heart Fail 2004; 6: 539–545 http://dx.doi.org/10.1016/j.ejheart.2004.04.013CrossrefGoogle Scholar

  • [26] Tang W.H., Vagelos R.H., Yee Y.G., et al. Neurohormonal and clinical responses to highversus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002; 39:70–78 http://dx.doi.org/10.1016/S0735-1097(01)01714-4CrossrefGoogle Scholar

  • [27] Vantrimpton P., Rouleau J.L., Ciampi A., Harel F., De Champlaint J., Bichet D., Moye JA. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular enlargement (SAVE) study. Eur Heart J 1998; 19: 1552–1563 http://dx.doi.org/10.1053/euhj.1998.1093CrossrefGoogle Scholar

  • [28] Shirani J., Dilsizian V. Imaging left ventricular remodeling: targeting the neurohumoral axis. Nat Clin Pract Cardiovasc Med 2008;5 Suppl 2:S57–62 http://dx.doi.org/10.1038/ncpcardio1244CrossrefGoogle Scholar

  • [29] Yancy C.W., Lee D.C. Personalized medicine in heart failure: are we there yet? J Am Coll Cardio Img 2012;5:419–421 http://dx.doi.org/10.1016/j.jcmg.2012.02.007CrossrefGoogle Scholar

  • [30] Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987;57:17–22 http://dx.doi.org/10.1136/hrt.57.1.17CrossrefGoogle Scholar

  • [31] Hillege H.L., Girbes A.R., de Kam P.J., Boomsma F., de Zeeuw D., Charlesworth A., Hampton J.R., van Veldhuisen D.J. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203–210. http://dx.doi.org/10.1161/01.CIR.102.2.203CrossrefGoogle Scholar

  • [32] Rossignol P., Cleland J.G., Bhandari S., Tala S., Gustafsson F., Fay R., Lamiral Z., Dobre D., Pitt B., Zannad F. Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction Insights From the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Circulation. 2012 Jan 17;125(2):271–279. Epub 2011 Nov 29. Google Scholar

  • [33] Gupta S., Neyses L. Diuretic usage in heart failure: a continuing conundrum in 2005. Eur Heart J. 2005;26:644–6 http://dx.doi.org/10.1093/eurheartj/ehi176CrossrefGoogle Scholar

  • [34] Ahmed A., Zannad F., Love T.E., et al. A propensity- matched study of the associationof low serum potassium levels and mortality in chronic heart failure. Eur Heart J 2007;28:1334–1343 http://dx.doi.org/10.1093/eurheartj/ehm091Web of ScienceCrossrefGoogle Scholar

  • [35] Brown J.R., Uber P.A., Mehra M.R. The progressive cardiorenal syndrome in heart failure: mechanism and therapeutic insights. Curr Treat Options Cardiovasc Med 2008; 10: 342–348 http://dx.doi.org/10.1007/s11936-008-0054-5CrossrefGoogle Scholar

  • [36] Weinfeld M.S., Chertow G.M., Stevenson L.W. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J. 1999; 138: 285–290 http://dx.doi.org/10.1016/S0002-8703(99)70113-4CrossrefGoogle Scholar

About the article

Published Online: 2014-02-04

Published in Print: 2014-02-01


Citation Information: Open Medicine, ISSN (Online) 2391-5463, DOI: https://doi.org/10.2478/s11536-012-0141-6.

Export Citation

© 2013 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Comments (0)

Please log in or register to comment.
Log in